Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Basilea Pharmaceutica ( (CH:BSLN) ) just unveiled an announcement.
Basilea Pharmaceutica announced a USD 30 million sales milestone payment triggered by strong sales of its antifungal drug Cresemba in Europe, managed by its license partner Pfizer. This milestone reflects the growing demand and significant medical need for Cresemba, which has seen a 27% increase in global sales over the past year, highlighting its importance in treating life-threatening invasive mold infections.
The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF53.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.
More about Basilea Pharmaceutica
Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000, focusing on discovering, developing, and marketing innovative drugs to treat severe infections caused by bacteria or fungi. The company has successfully brought to market two hospital-use drugs: Cresemba, for invasive fungal infections, and Zevtera, for bacterial infections. Basilea is listed on the Swiss stock exchange and has a portfolio of preclinical and clinical anti-infective programs.
Average Trading Volume: 40,171
Technical Sentiment Signal: Buy
Current Market Cap: CHF566.4M
Learn more about BSLN stock on TipRanks’ Stock Analysis page.